Clinical Trial Results:
A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus placebo followed by a 12 week treatment period with open-label Vildagliptin 100 mg o.a.d. as add-on therapy in patients with type 2 diabetes inadequately controlled with Metformin monotherapy
Summary
|
|
EudraCT number |
2007-000538-37 |
Trial protocol |
DE |
Global completion date |
07 Jul 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Oct 2016
|
First version publication date |
12 Oct 2016
|
Other versions |
|
Summary report(s) |
CLAF237ADE02_NovCTR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.